The Interuniversity Cardiology Institute of the Netherlands
11
0
0
7
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
9.1%
1 terminated/withdrawn out of 11 trials
87.5%
+1.0% vs industry average
18%
2 trials in Phase 3/4
14%
1 of 7 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (11)
PHOspholamban RElated CArdiomyopathy STudy - Intervention
Role: collaborator
Routine Versus Aggressive Upstream Rhythm Control for Prevention of Early Atrial Fibrillation in Heart Failure
Role: collaborator
The Dutch Asymptomatic Mitral Regurgitation Trial
Role: collaborator
NOACs for Atrial Tachyarrhythmias in Congenital Heart Disease
Role: collaborator
Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System
Role: collaborator
APRICOT-3: Antithrombotics in the Prevention of Reocclusion In COronary Thrombolysis -3
Role: collaborator
Transesophageal Echocardiography to Identify pAtients With Low Risk of Stroke in Atrial Fibrillation - TIARA Pilot Study
Role: lead
Effect of NT-proBNP Guided Treatment of Chronic Heart Failure
Role: collaborator
Clinical Study to Examine the Effects of Erythropoietin on Left Ventricular Function After Acute Myocardial Infarction
Role: collaborator
Evaluating Effects of a Left Bundle Branch Block
Role: collaborator
The Viability-Guided Angioplasty After Acute Myocardial Infarction-Trial (The VIAMI-Trial)
Role: collaborator
All 11 trials loaded